Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

6
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
6
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

187
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
187
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

10
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
10
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

8
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
8
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.1K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

555
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
555

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United States.

Journal of viral hepatitis·2026
Same author

Telomere biology disorders and hepatic disease.

Seminars in hematology·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology international·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Hepatology (Baltimore, Md.)·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Annals of hepatology·2026
Same author

A multisociety consensus statement on a new common definition and diagnostic criteria for PSVD or NCPF.

Journal of hepatology·2026

Related Experiment Video

Updated: Oct 4, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K

Chronic hepatitis D-What is changing?

David Yardeni1, Theo Heller1, Christopher Koh1

  • 1Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Journal of Viral Hepatitis
|February 5, 2022
PubMed
Summary
This summary is machine-generated.

Hepatitis D virus (HDV) infection, a chronic liver disease, is seeing new hope with emerging treatments like bulevirtide. These novel therapies in clinical trials offer a potential cure for this previously incurable condition.

Keywords:
chronic liver diseasehepatitis Dtreatment

More Related Videos

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.5K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.6K

Related Experiment Videos

Last Updated: Oct 4, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.3K
Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
11:14

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

Published on: November 7, 2018

18.5K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.6K

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis D virus (HDV) causes a severe chronic liver disease.
  • Current treatments are limited, leading to high risks of cirrhosis and liver cancer.
  • HDV infection remains a significant global health concern due to its severity and lack of effective therapies.

Purpose of the Study:

  • To review recent advances in Hepatitis D virus (HDV) therapeutics.
  • To highlight novel treatment options emerging from clinical trials.
  • To provide an overview of the evolving landscape of HDV treatment.

Main Methods:

  • Review of current scientific literature and clinical trial data.
  • Analysis of emerging therapeutic agents targeting HDV.
  • Synthesis of information on approved and investigational HDV treatments.

Main Results:

  • Bulevirtide, an HDV entry inhibitor, has received conditional authorization in Europe and is under review in the US.
  • Other promising agents in clinical trials include interferon lambda, lonafarnib, and nucleic acid polymers (NAPs).
  • These novel therapies represent a significant shift towards potentially curative options for HDV infection.

Conclusions:

  • The field of Hepatitis D virus (HDV) therapeutics is rapidly advancing.
  • Emerging treatments offer new hope for managing and potentially curing chronic HDV infection.
  • Continued research and clinical trials are crucial for developing definitive therapies.